VANCOUVER, British Columbia, Feb. 20, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that Dr. Mark Murray, President and CEO of Tekmira, will provide a corporate overview at the 2014 RBC Capital Markets' Global Healthcare Conference on Tuesday, February 25, 2014 at 3:05 pm ET at the New York Palace Hotel.
Webcast Information
A live webcast of this presentation can be accessed through the Investor section of Tekmira's website at www.tekmirapharm.com. A replay of webcast will be available on the Tekmira website following the event.
About Tekmira
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM) is a biopharmaceutical company focused on advancing novel RNA interference (RNAi) therapeutics and providing its leading lipid nanoparticle (LNP) delivery technology to its partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering its delivery technology. Further information about Tekmira can be found at www.tekmirapharm.com.
CONTACT: Investors
Jodi Regts
Director, Investor Relations
Phone: 604-419-3234
Email: jregts@tekmirapharm.com
Media
David Ryan
Longview Communications Inc.
Phone: 416-649-8007
Email: dryan@longviewcomms.ca
